All In Biotech

Drug Trial Radar · NCT07551804

Safety, Pharmacokinetic (PK) Profile and Efficacy of Inpegsomatropin Injection in Adults With Growth Hormone Deficiency

A Multiple-Dose, Dose-Escalation, Randomized, Double-Blind, Placebo-Controlled Phase Ⅱa Clinical Trial to Evaluate the Safety, Pharmacokinetic (PK) Profile and Preliminary Efficacy of Inpegsomatropin Injection in Adults With Growth Hormone Deficiency

Last checked: Nov 20, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Jun 10, 2026

Primary completion

Dec 31, 2027

Study completion Jun 30, 2028

Sponsor

Sponsor type
Industry
First posted
Apr 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multiple-dose, dose-escalation, randomized, double-blind, placebo-controlled phase Ⅱa clinical trial. A total of 36 adult participants with growth hormone deficiency will be enrolled sequentially in ascending dose cohorts, and within each dose cohort, participants will be randomized in a 3:1 ratio.

Conditions

  • Adult Growth Hormone Deficiency

Interventions

  • Inpegsomatropin InjectionDrug

    Inpegsomatropin Injection,initial dose1mg/0.25ml, s.c. ,once a week

  • Placebo for Inpegsomatropin InjectionDrug

    Placebo for Inpegsomatropin Injection,initial dose0.25ml, s.c. ,once a week

  • Inpegsomatropin InjectionDrug

    Inpegsomatropin Injection,initial dose 2mg/0.5ml, s.c. ,once a week

  • Placebo for Inpegsomatropin InjectionDrug

    Placebo for Inpegsomatropin Injection,initial dose 0.5ml, s.c. ,once a week

  • Inpegsomatropin InjectionDrug

    Inpegsomatropin Injection,initial dose 4mg/1ml, s.c. ,once a week

  • Placebo for Inpegsomatropin InjectionDrug

    Placebo for Inpegsomatropin Injection,initial dose 1.0ml, s.c. ,once a wee

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse EventTime frame: Day -1,Weeks 1, 3, 5, 9, 17, 25, 29, 37
  2. Serious Adverse EventTime frame: Day -1,Weeks 1, 3, 5, 9, 17, 25, 29, 37
  3. Number of Participants with Abnormal Laboratory Parameters FindingsTime frame: Day -1,Weeks 1, 3, 5, 9, 17, 25, 29, 37
  4. HR (bpm)Time frame: Day -1,Weeks 1, 3, 5, 9, 17, 25, 29, 37
  5. PR (ms)Time frame: Day -1,Weeks 1, 3, 5, 9, 17, 25, 29, 37
  6. QRS (ms)Time frame: Day -1,Weeks 1, 3, 5, 9, 17, 25, 29, 37
  7. QT (ms)Time frame: Day -1,Weeks 1, 3, 5, 9, 17, 25, 29, 37
  8. QTc (ms)Time frame: Day -1,Weeks 1, 3, 5, 9, 17, 25, 29, 37
  9. Number of participants with clinically significant changes in imaging examinationsTime frame: Day -1,Weeks 1, 3, 5, 9, 17, 25, 29, 37
  10. body weightTime frame: Day -1,Weeks 1, 3, 5, 9, 17, 25, 29, 37
  11. body Mass IndexTime frame: Day -1,Weeks 1, 3, 5, 9, 17, 25, 29, 37
  12. body temperatureTime frame: Day -1,Weeks 1, 3, 5, 9, 17, 25, 29, 37
  13. pulseTime frame: Day -1,Weeks 1, 3, 5, 9, 17, 25, 29, 37
  14. blood pressureTime frame: Day -1,Weeks 1, 3, 5, 9, 17, 25, 29, 37
  15. RespirationTime frame: Day -1,Weeks 1, 3, 5, 9, 17, 25, 29, 37
  16. Trunk fat percentageTime frame: Week 25
  17. Trunk fat massTime frame: Week 25
  18. Total fat massTime frame: Week 25
  19. Visceral adipose tissue (VAT)Time frame: Week 25
  20. Lean body mass (LBM)Time frame: Week 25
  21. Bone mineral density (BMD)Time frame: Week 25
  22. Quality of life score (QoL score)Time frame: Week 25
  23. BMITime frame: Week1Day1,Week25Day1
  24. Change from baseline in waist-to-hip ratioTime frame: Week3Day1,Week25Day1
  25. IGF-I /IGFBP-3Time frame: Week1Day1,Week25Day1
  26. CmaxTime frame: Week1Day1,Week25Day1
  27. CminTime frame: Week1Day1,Week25Day1
  28. TmaxTime frame: Week1Day1,Week25Day1
  29. AUC0-tTime frame: Week1Day1,Week25Day1
  30. AUC0-∞Time frame: Week1Day1,Week25Day1
  31. AUC0-tauTime frame: Week1Day1,Week25Day1
  32. Rac_CmaxTime frame: Week1Day1,Week25Day1
  33. Rac_AUC0-tauTime frame: Week1Day1,Week25Day1
  34. CL/FTime frame: Week1Day1,Week25Day1
  35. Vz/FTime frame: Week1Day1,Week25Day1
  36. DFTime frame: Week1Day1,Week25Day1
  37. t1/2Time frame: Week1Day1,Week25Day1
  38. ADATime frame: Week1Day1,Week29Day1
  39. NAbTime frame: Week1Day1,Week29Day1

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, China · Recruiting

  • The First Affiliated Hospital of Henan University of Science and Technology

    Henan, China · Recruiting

  • Huashan Hospital, Fudan University

    Shanghai, China · Recruiting

  • West China Hospital, Sichuan University

    Sichuan, China · Recruiting

  • The First Affiliated Hospital of Xiamen University

    Xiamen, China · Recruiting

  • The Second Affiliated Hospital, Zhejiang University School of Medicine

    Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.